Biological and Computational Approach to Modify Bacterial Size and Reduce its Antibiotic Consumption Targeting MREB Bacterial Cytoskeletal Protein

Prarthana J^{1,*} Nayana B,¹ Jayanthi MK,² Chagalamari Akhila,²

Shashank M Patil³ and Ramith Ramu³

¹Department of Biotechnology, Sri Dharmasthala Manjunatheshwara College, Ujire, Karnataka, India

²Department of Pharmacology, JSS Medical College, JSS Academy

of Higher Education and Research, Mysuru, Karnataka, India

³Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS

Academy of Higher Education and Research, Mysuru, Karnataka, India.

ABSTRACT

Amongst the cytoskeletal proteins of bacteria, MreB is known to have very crucial role in modulating shape of the bacteria. Present study involves the use of biocide (A-22) which minimizes the bacterial size augmenting with minimal antibiotic consumption. Intended experiment is designed to be carried out on selected pure strains of gram-positive and gram-negative bacteria namely *Lactobacillus rhamnosous* ATCC 7469 and Pseudomonas aeruginosa ATCC 27853 respectively. The pure strains are exposed to biocide and changes in the shape is recorded by means of Foldscope (Origami based paper microscope, Prakash Labs) and in-vivo assessment done using antibiotic sensitivity assays with different antibiotics. The novel biocide specifically targeting bacterial cytoskeletal protein, that determines rod shape among bacterial population. The said compound is also experimented as combinational drug along with conventional antibiotic usage. In *Pseudomonas aeruginosa* ATCC 27853 when tested for MIC using A-22 and different antibiotics, it was found that 0.5 μ g/ml of ampicillin, 1 μ g/ml of streptomycin and 5 μ g/ml erythromycin were effective in curtailing bacteria against conventional antibiotic concentrations ampicillin 128 μ g/ml streptomycin 32 μ g/ml, erythromycin 64 μ g/ml. Compared to doses of antibiotics required to kill bacteria, the combinational drug of biocide and antibiotic have shown promising effects in killing bacteria at very less concentration, this can useful for treating most diseases caused by antimicrobial resistance bacterial populations.

KEY WORDS: ANTIBIOTIC SENSITIVITY, BIOCIDE, CYTOSKELETAL PROTEINS, FOLDSCOPE, MREB.

INTRODUCTION

Eukaryotes and prokaryotes contain cytoskeletal protein structures that are essential to stabilize cell membrane and also provide rigidity to the cell (Soufo and Graumann 2007; Vats et al. 2009). In prokaryotes it helps in maintaining cell morphology, cell growth, cell division and chromosome segregation. The cytoskeletal proteins of eukaryotes namely actin, tubulin, and intermediate filaments are homologous to cytoskeletal proteins of bacteria MreB, FtsZ, and crescentin respectively (Daisuke et al. 2008). Among these, MreB protein determines rod-shape in bacteria: MreB which is an actin homolog is recognized as significant protein in

Article Information:*Corresponding Author: prarthanarao6@gmail.com Received 25/12/2021 Accepted after revision 28/02/2022 Published: 30th March 2022 Pp- 70-76 This is an open access article under Creative Commons License, https://creativecommons.org/licenses/by/4.0/. Available at: https://bbrc.in/ DOI: http://dx.doi.org/10.21786/bbrc/15.1.11 maintaining rod shape in the bacteria such as *Pseudomonas* aeruginosa, Escherichia coli, Caulobacter and Bacillus subtilis (Busiek et al. 2015; Awunii 2020).

It was first identified in *Escherichia coli* as a protein necessary in maintaining cell shape (Doi et al. 1988). MreB belongs to the superfamily of HSP70–actin–sugar kinase and it was known in forming spirals which can traverse the longitudinal axis of cells of *B. subtilis*, this suggests that bacteria are having an internal actin-like cytoskeleton to maintain cell shape which is analogous to eukaryotes (Jones et al. 2001; Awuni and Mu 2019). It is considered to be conserved actin homolog in prokaryotes and is mainly encoded in the chromosomes of the bacterial species and also helps in variety of cellular activities. A22 - biocide changing rods into cocci: S-(3,4-dichlorobenzyl) isothiourea



Prarthana J et al.,

(A22) biocide is a derivative of S-benzylisothiourea which is chemically designated as [(3,4-dichlorophenyl)methyl] thiocarboxamidine (Figure 1) (Iwai et al. 2002; Carballido-Lopez et al. 2006; Awunii 2020).



The A22 is known to be acting like a reversible inhibitor of a bacterial cell wall protein MreB which leads to change in shape of bacteria from rods to the coccoid form and also it prevents assembly of MreB into long rigid polymers. As a result of change in shape various properties of the bacteria can be affected, such as the cell division, the acquisition of nutrients, motility, the clamping surfaces, and pathogenesis (Bonez et al. 2016). To check the activity of A22 in changing rods to cocci the pure strains were used in this study which includes *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922, *Lactobacillus rhamnosus* ATCC 7469 and Lactobacillus casei ATCC 393 (Valik et al. 2008; Percival and Williams 2014; Moradali et al. 2016; Awuni 2020).

P. aeruginosa and *E. coli* were used in the study as they are pathogenic microorganisms and they show resistance to most of the antibiotics. As a case combination of biocide and antibiotics are used to inhibit the bacterial growth. In the current scenario, several phytochemical formulations have been used to treat microbial diseases (Patil et al. 2021a; Patil et al. 2021b; Patil et al. 2021c). Small molecules like bioactive peptides have also been used, indicating the significance of small chemical compounds (Patil et al. 2020). In the present study MreB polymerization is targeted using A22, MreB is very essential for cell wall biosynthesis and is also conserved in all rod shaped bacteria. This study mainly involves the use of combination of biocide and antibiotics against strains such as P. aeruginosa and E. coli because of their resistance to almost all the antibiotics. Their size reduction is established with minimum amount of conventional antibiotic to kill them. By this treatment of many severe diseases caused by these bacteria can be made possible.

MATERIAL AND METHODS

The pure strains of the bacteria from ATCC were taken and streaked on the agar plates. *Pseudomonas aeruginosa* and *Escherichia coli* was grown on Nutrient agar (NA) and incubated at 37°C for 24 hrs whereas, *Lactobacillus rhamnosus* was grown on De Man, Rogosa and Sharpe (MRS) agar and incubated at 37°C for 24 hrs (Bonez et al. 2016). Different broth was used for inoculating different bacteria. For *P. aeruginosa* Mueller Hinton borth (MHB) and agar was used for inoculating and plating respectively, whereas for *E. coli* Luria bertani broth and agar (LBA) was used for inoculation and plating respectively. *L. rhamnosus* was inoculated and plated on MRS media. Initially the cultures were exposed to different concentration of biocide (A22) given in the Table 1 and incubated at 37°C for 24 hrs.

After 24 hrs, the optical density of the culture was measured at 660nm using UV-VIS Double Beam Spectrophotometer 2205 (Systronics) and the size of the bacteria was measured using micrometry shown in the Table 2 (Awuni and Mu 2019). Then the lawn culture was prepared using sterile swab and different concentration of antibiotics was added and plates were incubated at 37°C for 24 hrs and the zone of inhibition was measured which is given in the Table 3. The bacteria were inoculated with combination of biocide and antibiotics and after 24 hrs of exposure the optical density of the culture was measured using UV-VIS Double Beam Spectrophotometer 2205 (Systronics), and the graph obtained is given in the Figures below (Al-Khayyat et al. 2019). Molecular docking simulation is performed to understand the interaction of ligands with the target proteins at the molecular level. In this study, the crystallographic structure of MerB protein was retrieved from the RCSB PDB database (PDB ID: 1JCE).

On the other hand, chemical structure of the compound A-22 was drawn and 3D optimized using ChemSketch. Protein and ligand preparation, as well as binding site prediction steps were completed according to the previous studies conducted by Patil et al. (2021d) and Patil et al. (2021e). AutoDock Vina 1.2, an open-source command line software designed for the docking of the molecular entities was used for the docking simulation (Trot and Olson 2010). The visualization of docking simulation was done using BIOVIA Discovery Studios Visualizer (2021), an open source visualizing GUI software. Druglikeliness and pharmacokinetic analysis, also known as ADMET (adsorption, distribution, metabolism, excretion, and toxicity) predictions, were performed to assess its oral bioavailability of potential drug candidates in silico. In this study, chemical structure of the compound A-22 in SMILES format was submitted to the ADMETlab server (https://admetmesh.scbdd.com/).

For the druglikeliness evaluation, Lipinski's rule of five was considered. For pharmacokinetic evaluation, CACO-2 permeability, human intestinal absorption (HIA), volume distribution (VD), cytochrome P (CYP) inhibition, hERG blocking, and AMES toxicity parameters were considered (Patil et al. 2021f). As the druglikeliness and pharmacokinetic studies were performed in silico, there were no ethical clearance, patient consent, or any kind of approvals required.

RESULTS AND DISCUSSION

The different bacterial cultures viz., *P. aeruginosa, E. coli* and *L. rhamnosus* were exposed with 1, 3 and 0.5 μ g/ml concentration of the biocide. The optical density of the culture after exposure with biocide and control (without biocide) was recorded and also the size of the bacteria

measured is given in the Table 1. After the cultures were exposed to biocide, they were subjected to antibiotic assay against different antibiotics and the zone of inhibition formed is given in the Table 2. The optical density of the culture was recorded and the graph obtained is shown below (Figure 2, 3, and 4). The MIC of the experimental molecules has been shown in Figure 5.

Table 1. Optical density and the size of the bacteria after exposure to A-22 biocide							
Bacteria	Biocide concentration	Optical density (660nm)	Size (µm)				
Pseudomonas aeruginosa	Control	0.612	7.5				
	l μg/ml	0.410	5.0				
Escherichia coli	Control	1.453	2.5				
	3 µg/ml	0.751	1.875				
Lactobacillus rhamnosus	Control	1.684	8.0				
	0.5 µg/ml	1.571	7.5				

Table 2. Zone of inhibition formed using different concentration of different antibiotics								
P. eruginosa - 1 μg/ ml			L. rhamnosus - 0.5 µg/		<i>E. coli</i> – 3 µg/ ml biocide			
biocide concentraton		ml biocide concentration		concentration				
Ampicillin	0.5	8	Erythromyein	5	13	Ampicillin	1	N.Z
	1.0	9		10	16		2	N.Z
	1.5	10		15	18		3	N.Z
	2.0	12		20	20		4	14
	5	8		2	8	Erythromyein	10	12
Streptomy cin	10	11	Chloramphenicol	4	13		20	14
	15	12		6	15		30	14
	20	13		8	18		40	14
	5	10	Streptomycin	2	7		0.012	N.Z
Erythromycin	10	13		5	11	Ciprofloxacin	0.013	N.Z
	15	15		7	14		0.014	10
	20	15		10	18		0.015	14
_	5	11	Note:	All	the		1	N.Z
Chloramphenicol	10	13	concentrations are given			.u	2	9
	15	15	in µg∕	ml, whereas the		otomy (3	10
	20	16	zone in	hibition i	s given in	Strep	4	10
	0.2	7	mm.			N.Z.: 1	No zone obs	erved during
Ciprolloxacin	0.3	9				the exp	eriment	
	0.4	10						
	0.5	11						

Figure 2: Graphs showing growth percentage of *Pseudomonas aeruginosa* against different experimental compounds A) ampicillin, B) streptomycin, C) erythromycin, D) chloramphenicol, and E) ciprofloxacin



Figure 3: Graphs showing growth percentage of *Lactobacillus rhamnosus* against different experimental compounds A) erythromycin, B) streptomycin, and C) chloramphenicol



During the molecular docking process compound A-22 formed 3 hydrogens with GLY 68, PRO 103, and THR 158 residues of the protein. It also formed 2 hydrophobic alkyl bonds with LEU 312 and VAL 315. In addition, an electrostatic pi-anion bond with ASP 9 of the protein. The compound was predicted with a binding affinity of -8.7

Figure 4: Graphs showing growth percentage of *Escherichia coli* against different experimental compounds A) ampicillin, B) streptomycin, C) erythromycin, D) ciprofloxacin



Figure 5: Image of *Pseudomonas aeruginosa* culture showing zone of inhibition for different concentration of A and B) ampicillin, C) streptomycin, D) Image of *Lactobacillus rhamnosus* culture showing zone of inhibition (diffuse growth present) for different concentration of streptomycin without exposing to biocide, E) after biocide exposure



kcal/mol. The binding interaction of A-22 with MerB has been visualized in Figure 6. The bound amino acids have been colorized according to their binding type. Whereas, the surrounding amino acids have been colored in teal.

During the evaluation of druglikeliness according to the Lipinski rule, the molecular weight (MW) of A-22 was found to be 227.07 g/mol, which has not exceeded the limit of 500 g/mol. clogP value represents the partition coefficient between n-octanol and water to measure the hydrophilicity. Low hydrophilicities and therefore high clogP values cause

poor absorption or permeation. In this study, the clogP was found to be 1.65. Hydrogen bond acceptors were predicted to be 2, whereas the limit has been set for 10. In case of hydrogen bond donors, A-22 was predicted to have 2, with the limit set for 5. Therefore, compound A-22 never violated the rule of Lipinski rule. In case of pharmacokinetic analysis, Caco-2 cell line permeability was predicted to be -4.97 for A-22.



The limit of Caco-2 value is -5.15 log units. Human intestinal absorption value was predicted to be positive (0.008). Volume distribution was predicted to be 4.628, which should be in the range of 0.04-20L/kg. In case of cytochrome P inhibition, A-22 was predicted with no inhibition of cytochrome P enzymes. The human Ether-à-go--Related Gene (hERG) is blocking was predicted with positive value (0.032). Furthermore, AMES toxicity value was predicted to be positive (0.236), which indicated absence of risk of toxicity. Table 3 represents the druglikeliness and pharmacokinetic analysis of the compound A-22. Figure 7 visualizes the druglikeliness and pharmacokinetic analysis of A-22.

Figure 7: Visualization of druglikeliness and pharmacokinetic



The alarming increase in antibiotic resistance is due poor public health, inexpensive antibiotics which is causing threats in neonatal sepsis, causing therapeutic failures in bacterial infections (Laxminarayan et al. 2015). It is alarming that although bacterial resistance continues to emerge, the rate at which antibiotics are being developed is decreasing (Pulcini et al. 2012). MreB is a promising drug target because it is conserved and essential in most rodshaped bacteria, MreB has been associated with essential subcellular processes including cell wall biosynthesis and maintenance of cell shape (Doi et al. 1988; Bean and Amann 2008; Awuni 2020). Determinations of the DNA-sequence of the MreB-gene and of the gene-products of the Mre-region that function in formation of the rod shape of Escherichia coli cells, cell division, cell wall morphogenesis MreB have been identified as potential targets for antibiotics.

The nucleotide binding site is an important target for antibiotics development because nucleotide binding plays a crucial role in the structure and dynamics of MreB (Wachi and Matsuhashi 1989; Jones et al. 2001; Soufo and Graumann 2005; Bean and Amann 2008; Awuni and Mu 2019). ATP induces the polymerization of MreB into filaments required for cell wall biosynthesis (. Interestingly, the polymerization of MreB induces ATP hydrolysis, which serves as a timing process to coordinate depolymerization (Bean and Amann 2008; Gunning et al. 2015). Thus, ATP is required by MreB to function properly and any molecule that could compete with ATP for binding to the nucleotide binding pocket could be a bactericidal agent (Awuni 2020).

The results obtained from this study are the first to evaluate the effectiveness of biocide A22 by inhibiting cytoskeletal protein Mreb on the strains Pseudomonas aeruginosa ATCC 27853 and Lactobacillus rhamnosus ATCC 7469 and to reduce consumption of antibiotics due to decreased size. The MIC value of A22 on *Pseudomonas aeruginosa* was found be lower in this study, compared to the MIC reported in previous studies (Bonez et al. 2016). The drastic reduction in the antibiotic consumption, below MIC after the exposure of the strains to biocide was observed in this study. The result reported in the study provides an alternative method to inhibit multi-drug resistant (MDR) microorganisms. The results obtained helps indicates that the biocide A22 used in the study brought about change in bacterial conformation by targeting its cytoskeletal protein MreB, and also reduced antibiotic consumption of bacteria (Awuni 2020).

Apart from the *in vitro* evaluations, *in silico* studies conducted on MreB inhibition also indicates that compound A-22 has the higher inhibitory potential. A recent study showed that MreB protein can be inhibited by few of the 100 natural compounds tested. Apart from amentoflavone and rutin, the other compounds failed to achieve significant inhibition. The compounds were also reported with insignificant druglikeliness and pharmacokinetics results (Al-Khayyat et al. 2019). In another study, phytochemicals from Leucas aspera were screened for the inhibition of MerB in silico. Among them, leucasperone B and penicillin were found to be the potent inhibitors of the protein. However, compound A-22 has been proved with the better

74 TO MODIFY BACTERIAL SIZE AND REDUCE ANTIBIOTIC CONSUMPTION

Prarthana J et al.,

outcomes during in silico analysis in comparison with these studies, with respect to binding interaction, druglikeliness and pharmacokinetics analysis. From these we can say that A22 can be used as a novel drug for treating diseases caused by MDR *Pseudomonas aeruginosa* and also usage of high dose antibiotics can be stopped which can prevent many side effects caused by antibiotics to humans (Sharavanan et al. 2019; Awuni 2020).

Table 3. Druglikeliness and pharmacokinetic analysis of compound A-22.						
Categories	Types of parameters	A-22				
Druglikeliness based on Lipinski's rule of five	Molecular weight	227.07 g/mol				
	No. of hydrogen bond donors	2				
	No. of hydrogen bond acceptors	2				
	cLog P	1.65				
Adsorption	Caco-2 permeability	-4.97				
	Human intestinal absorption (HIA)	0.008				
Metabolism	CYP1A2 inhibition	No				
	CYP2C19 inhibition	No				
	CYP2C9 inhibition	No				
	CYP2D6 inhibition	No				
	CYP3A4 inhibition	No				
hERG blocking	Clearance (CL)	0.032				
Toxicity	AMES toxicity	0.236				
Distribution	Volume distribution (VD)	0.071				

CONCLUSION

The findings of this study are the first to assess the efficacy of biocide A22 in suppressing the cytoskeletal protein MreB of *Pseudomonas aeruginosa* ATCC 27853 and Lactobacillus rhamnosus ATCC 7469, as well as the reduction in antibiotic consumption due to reduced size. This study discovered a significant decrease in antibiotic consumption below the MIC level and there is nearly 60-70 percent antibiotic usage after the strains were exposed to biocide. In addition, our computational investigation also suggests that biocide A-22 inactivates MreB. During druglikeliness and pharmacokinetics analysis reveals A-22 shows no toxic effects. Therefore, we conclude biocide A-22 as a potent anti-bacterial agent against MDR bacterial species.

ACKNOWLEDGEMENTS

This study was financially supported by the DBT (Sanction Order No.BT/IN/Indo-US/Foldscope/39/2015) in partnership with Foldscope Instruments Inc. and Prakash lab (Stanford University; California) from 2018-2019.

Conflict of Interests: Authors declare no conflicts of interests to disclose.

Data Availability Statement: The database generated and /or analysed during the current study are not publicly available due to privacy, but are available from the corresponding author on reasonable request.

REFERENCES

Al-Khayyat, M. Z., Ameen, A. G., and Abdulla, Y. A. (2019). Virtual Screening for Inhibitors Targeting the Rod Shape-Determining Protein in *Escherichia coli*. Jordan J Biol Sci 12(2).

Awuni, E., and Mu, Y. (2019). Effect of A22 on the conformation of bacterial actin MreB. Int J Mol Sci 20:1304.

Bean, G. J., and Amann, K. J. (2008). Polymerization properties of the Thermotoga maritima actin MreB: roles of temperature, nucleotides, and ions. Biochemistry 47, 826–835.),

Bonez P. C., Ramos, A. P., Nascimento K., et al. (2016). Antibacterial, cyto and genotoxic activities of A22 compound ((S-3,4-dichlorobenzyl) isothiourea hydrochloride). Microb Pathog 99 14–18.

Bratton, B.P., Shaevitz, J.W., Gitai, Z. et al. (2018). MreB polymers and curvature localization are enhanced by RodZ and predict E. coli's cylindrical uniformity. Nat Commun 9(1), 1-11.

Busiek, K. K., and Margolin, W. (2015). Bacterial actin and tubulin homologs in cell growth and division. Curr Biol 25, R243–R254.

Carballido-López, R., Formstone, A., Li, Y., et al. (2006). Actin homolog MreBH governs cell morphogenesis by localization of the cell wall hydrolase LytE. Dev Cell. 11(3); 399-409

Daisuke, S., Masako, S., and Hironori, N. (2008).

Determination of bacterial rod shape by a novel cytoskeletal membrane protein. EMBO J 27(23):3081-91

Doi, M., Wachi, M., Ishino, F., et al. (1988). Determinants of the DNA sequence of the mreB gene and of the gene products of the mre region that function in formation of the rod shape of *Escherichia coli*. J Bacteriol 170, 4619–4624.

Awunii, E., (2020). Status of targeting MreB for the development of antibiotics. Front Chem. http://doi. org/10.3389/fchem.2019.00884

Figge, R. M., Divakaruni, A. V., and Gober, J. W. (2004). MreB, the cell shape-determining bacterial actin homologue, co-ordinates cell wall morphogenesis in Caulobacter crescentus. Mol Microbiol 51(5), 1321–1332.

Gunning, P. W., Ghoshdastider, U., Whitaker, S., et al. (2015). The evolution of compositionally and functionally distinct actin filaments. J Cell Sci 128, 2009–2019.

Harold, P. E. (2017). The discovery of the prokaryotic cytoskeleton: 25th anniversary. Mol Biol Cell. 28(3): 357–358.

Iwai N., Nagai K., and Wachi M. (2002). Novel S-benzylisothiourea compound that induces spherical cells in *Escherichia coli* probably by acting on a rod-shape-determining protein(s) other than penicillin-binding protein 2. Biosci Biotechnol Biochem 66:2658–2662.

Jones, L. J. F., Carballido-López, R., and Errington, J. (2001). Control of cell shape in bacteria: helical, actin-like filaments in *Bacillus subtilis*. Cell 104, 913–922.

Laxminarayan, R., Matsoso, P., Pant, S., et al. (2015). Access to effective antimicrobials: a worldwide challenge. Lancet 387: 168–175

Lim, J.Y., Yoon, J.W. and Hovde, C.J., (2010). A Brief Overview of *Escherichia coli* O157:H7 and Its Plasmid O157. J Microbiol Biotechnol. 20(1): 5–14.

Moradali, M.F., Ghods, S. and Rehm, B.H. (2017). *Pseudomonas aeruginosa* lifestyle: a paradigm for adaptation, survival, and persistence. Front Cellular Infect Microbiol 7, 39.

Patil, S. M., Kumari, V. C., Sumana, K., et al. (2021c).
Sustainable development of plant tissue culture industry: The Indian scenario. J Appl Biol Biotechnol 9(2): 18-27.
Patil, S. M., Maruthi, K. R., Naik, S., et al. (2021f).
Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS- CoV-2 RNA dependent RNA polymerase (RdRp). Bioinformation 17(11); 932-933.

Patil, S. M., Ramu, R., Shirahatti, P. S., et al. (2021b). A systematic review on ethnopharmacology, phytochemistry and pharmacological aspects of Thymus vulgaris Linn. Heliyon, 7(5):e07054.

Patil, S. M., Shirahatti, P. S., and Ramu, R. (2021a). Azadirachta indica A. Juss (neem) against diabetes mellitus: a critical review on its phytochemistry, pharmacology, and toxicology. J Pharm Pharmacol https:// doi.org/10.1093/jpp/rgab098

Patil, S. M., Sujay, S., Tejaswini, M., et al. (2020). Bioactive peptides: its production and potential role on health. Int J Innov Sci Eng Technol. (7) 167-182.

Patil, S.M., Martiz, R.M., Ramu, R., et al. (2021d). Evaluation of flavonoids from banana pseudostem and flower (quercetin and catechin) as potent inhibitors of α -glucosidase: an in silico perspective. J Biomol Struct Dyn. 1-15. DOI: 10.1080/07391102.2021.1971561

Patil, S.M., Martiz, R.M., Ramu, R., et al. (2021e). In silico identification of novel benzophenone-coumarin derivatives as SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors. J Biomol Struct Dyn. 1-17. DOI: 10.1080/07391102.2021.1971598

Percival, S., and Williams, D. (2014). *Escherichia coli*. In Microbiology of Waterborne Diseases. Academic Press USA (2) Pages 89-117.

Peter, L.G., (2007). Cytoskeletal elements in bacteria. Annu Rev Microbiol. 61:589-618.

Pulcini, C., Bush, K., Craig, W.A., et al. (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 54, 268–274.

Sharavanan, V.J., Sivaramakrishnan, M., Kothandan, R., et al. (2019) Molecular docking studies of phytochemicals from Leucas aspera targeting *Escherichia coli* and *Bacillus subtilis* subcellular proteins. Pharmacogn J. 11(2).

Soufo, H. J. D., and Graumann, P. L. (2005). *Bacillus subtilis* actin-like protein MreB influences the positioning of the replication machinery and requires membrane proteins MreC/D and other actin-like proteins for proper localization. BMC Cell Biol. 6:10.

Trott, O. and Olson, A.J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455-61.

Valík, L., Medvedová, A., Čižniar, M., et al. (2008). Characterization of the growth of Lactobacillus rhamnosus GG in milk at suboptimal temperatures. J Food Nutr Res 47, 60-67.

Vats, P., Yu, J. and Rothfield, L. (2009). The dynamic nature of the bacterial cytoskeleton. Cell Mol Life Sci. 66(20): 3353–3362.

Wachi, M., and Matsuhashi, M. (1989). Negative control of cell-division by MreB, a gene that functions in determining the rod shape of *Escherichia coli* cells. J. Bacteriol. 171, 3123–3127.

Weng, Y., Chen, F., Liu, Y., et al. (2016). *Pseudomonas aeruginosa* Enolase Influences Bacterial Tolerance to Oxidative Stresses and Virulence. Front microbial 7.